• Renal Cell Cancer
    • Virpi Launonen
    • Virpi Launonen: Influence Statistics

      Virpi Launonen

      Virpi Launonen

      STUK-Radiation and Nuclear Safety Authority, Helsinki, Finland. | STUK-Radiation and Nuclear Safety Authority, Helsinki, Finland | STUK – Radiation and Nuclear Safety ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Virpi Launonen:Expert Impact

      Concepts for whichVirpi Launonenhas direct influence:Renal cell cancer,Breast cancer,Fumarate hydratase,Fh mutations,Hereditary leiomyomatosis,Fh mutation,Pituitary adenoma predisposition,Germline mutations.

      Virpi Launonen:KOL impact

      Concepts related to the work of other authors for whichfor which Virpi Launonen has influence:Breast cancer,Microsatellite instability,Renal cell,Hereditary leiomyomatosis,Pituitary adenomas,Uterine leiomyomas,Dna methylation.

      KOL Resume for Virpi Launonen


      STUK-Radiation and Nuclear Safety Authority, Helsinki, Finland.


      STUK-Radiation and Nuclear Safety Authority, Helsinki, Finland


      STUK – Radiation and Nuclear Safety Authority, Laippatie, Helsinki, Finland


      Department of Medical Genetics, University of Helsinki


      Authors' Affiliations: Department of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Henry Wellcome Building for Molecular Physiology, University of Oxford, and Molecular and Population Genetics and Molecular Cytogenetics and Microscopy Core, Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom; Cancer Research UK and Engineering and Physical Sciences Research Council Cancer Imaging Centre, The Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Bioinformatics and Biostatistics, Experimental Pathology, and Histopathology Laboratory, Cancer Research UK London Research Institute, The Rayne Institute, University College London Division of Medicine, Royal Marsden Hospital, and Department of Histopathology, Imperial College, Hammersmith Hospital, London, United Kingdom; Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Cambridge, United Kingdom; Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York; Biomedical Sciences Department, College of Veterinary Medicine, Cornell University, Ithaca, New York; Department of Medical Genetics, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland; and Laboratory of Cancer Genetics, Institute for Cancer Research and Treatment, Candiolo, Turin, Italy


      Department of Medical Genetics, Biomedicum Helsinki, University of Helsinki, PO Box 63 (Haartmaninkatu 8), FIN‐00014, Finland


      Department of Medical Genetics and


      Department of Medical Genetics, Molecular and Cancer Biology Research Program, University of Helsinki, 00014 Helsinki, Finland


      Department of Medical Genetics, Molecular and Cancer Biology Research Program, 00014 University of Helsinki, Helsinki, Finland.


      Department of Medical Genetics, Biomedicum Helsinki (Haartmaninkatu 8), University of Helsinki, Helsinki FIN-00014, Finland


      Department of Medical Genetics, Biomedicum Helsinki, University of Helsinki, (Haartmaninkatu 8), Helsinki, P.O. Box 63, FIN-00014, Helsinki, Finland


      Department of Medical Genetics, Biomedicum Helsinki, Haartmaninkatu 8, PO Box 63, FIN-00014 University of Helsinki, Finland


      University of Helsinki, Finland

      Department of Medical Genetics, Biomedicum Helsinki, PO Box 63 (Haartmaninkatu 8), FIN-00014


      Department of Medical Genetics, Haartman Institute, University of Helsinki, P. O. Box 21, FIN-00014, Helsinki, Finland;


      Department of Clinical Genetics, University of Oulu and Oulu University Hospital, Finland


      Departments of Clinical Genetics, Mathematical Science/Statistics, Oncology and Radiotherapy, University of Oulu/Oulu University Hospital, Oulu, Finland


      Department of Clinical Genetics, University of Oulu/Oulu University Hospital, Kajaanintie 50, FIN-90220, Oulu, Finland


      Biocenter Oulu, World Health Organization Collaborating Center for Research in Human Reproduction and Department of Clinical Chemistry, University of Oulu, Oulu, Finland


      Department of Genetics, University of Oulu, 90570, Oulu, Finland

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Virpi Launonen is among the top experts in the world.
      Concept World rank
      protracted exposure emt #1
      human lkb gene #1
      c6 repeat #1
      cocultures emt #1
      hydratase mutations #1
      human lkb #1
      positive emt controls #1
      leiomyomas skin #1
      pjs genetic mutation #1
      leiomyomatosis skin #1
      stromal component tgfβ #1
      emt protracted exposure #1
      mutations pjs families #1
      emt radiation #1
      01 1 tgfβ #1
      tgfβ treated samples #1
      pjs families review #1
      lung bronchial epithelium #1
      605839 #1
      fumarate hydratase mutations #1
      official hugo symbol #1
      c6 repeat 125 #1
      presence stromal component #1
      finnish population ile157 #2
      tslc1 cpg #2
      database fumarate #2
      cancer chk2 #2
      leiomyomatosis metabolism #2
      fh germline #2
      5 missense variants #2
      fh gene deletion #2
      brca1 finnish #2
      fh mutation database #2
      tslc1 promoter region #2
      1q43 predispose #2
      rcc uterine #2
      chk2 gene families #2
      cancer lfl #2
      breast cancer chk2 #2
      hlrcc tumor syndrome #2
      neoplasms leiomyoma #2
      missensetype mutation #2
      tgfβ cocultures #2
      patients mcul #2
      Sign-in to see all concepts, it's free!

      Prominent publications by Virpi Launonen

      KOL-Index: 11811

      Since the identification of the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes, mutation analyses have been carried out in different populations. Here we screened 15 Turkish breast and breast-ovarian cancer families for mutations in both genes by conformation-sensitive gel electrophoresis (CSGE) and the protein truncation test (PTT), followed by DNA sequencing. Three families included a male breast cancer case, one without family history. Three germline mutations were ...

      Known for Breast Cancer | Mutation Brca2 | Male Female Genes | Germline Brca1 | Ovarian Neoplasms
      KOL-Index: 11573

      CONTEXT: Germline mutations in the MEN1 gene predispose to multiple endocrine neoplasia type 1 (MEN1) syndrome, but in up to 20-25% of clinical MEN1 cases, no MEN1 mutations can be found. Recently, a germline mutation in the CDKN1B gene, encoding p27(Kip1), was reported in one suspected MEN1 family with two acromegalic patients.

      OBJECTIVE: Our objective was to evaluate the role of CDKN1B/p27(Kip1) in human tumor predisposition in patients clinically suspected of MEN1 but testing negative ...

      Known for Multiple Endocrine Neoplasia | Germline Cdkn1b | Pituitary Adenoma | Men1 Mutations | Kinase Inhibitor
      KOL-Index: 11386

      BACKGROUND: Fumarate hydratase (HGNC approved gene symbol - FH), also known as fumarase, is an enzyme of the tricarboxylic acid (TCA) cycle, involved in fundamental cellular energy production. First described by Zinn et al in 1986, deficiency of FH results in early onset, severe encephalopathy. In 2002, the Multiple Leiomyoma Consortium identified heterozygous germline mutations of FH in patients with multiple cutaneous and uterine leiomyomas, (MCUL: OMIM 150800). In some families renal ...

      Known for Fh Mutation | Fumarate Hydratase | Online Database | Fumarase Deficiency | Tumor Suppressor
      KOL-Index: 11240

      In the Finnish breast and ovarian cancer families six BRCA1 and five BRCA2 mutations have been found recurrently. Some of these recurrent mutations have also been seen elsewhere in the world, while others are exclusively of Finnish origin. A haplotype analysis of 26 Finnish families carrying a BRCA1 mutation and 20 families with a BRCA2 mutation indicated that the carriers of each recurrent mutation have common ancestors. The common ancestors were estimated to trace back to 7–36 ...

      Known for Brca2 Mutations | Founder Effects | Finland Brca1 | Common Ancestors | Cancer Families
      KOL-Index: 10788

      Uterine leiomyomata (fibroids) are common and clinically important tumors, but little is known about their etiology and pathogenesis1,2,3. We previously mapped a gene that predisposes to multiple fibroids, cutaneous leiomyomata and renal cell carcinoma to chromosome 1q42.3–q43 (refs 4–6). Here we show, through a combination of mapping critical recombinants, identifying individuals with germline mutations and screening known and predicted transcripts, that this gene encodes fumarate ...

      Known for Uterine Fibroids | Papillary Carcinoma | Fh Predispose | Renal Cell | Germline Mutations
      KOL-Index: 10599

      Pituitary adenomas are common neoplasms of the anterior pituitary gland. Germ-line mutations in the aryl hydrocarbon receptor-interacting protein (AIP) gene cause pituitary adenoma predisposition (PAP), a recent discovery based on genetic studies in Northern Finland. In this population, a founder mutation explained a significant proportion of all acromegaly cases. Typically, PAP patients were of a young age at diagnosis but did not display a strong family history of pituitary adenomas. ...

      Known for Pituitary Adenoma Predisposition | Aip Mutations | Molecular Diagnosis | Hydrocarbon Receptor | Interacting Protein
      KOL-Index: 10073

      Germline mutations in the fumarate hydratase (FH) gene at 1q43 predispose to dominantly inherited cutaneous and uterine leiomyomas, uterine leiomyosarcoma, and papillary renal cell cancer (HLRCC syndrome). To evaluate the role of FH inactivation in sporadic tumorigenesis, we analyzed a series of 299 malignant tumors representing 10 different malignant tumor types for FH mutations. Additionally, 153 uterine leiomyomas from 46 unselected individuals were subjected to and informative in ...

      Known for Fumarate Hydratase | Uterine Leiomyomas | Fh Mutations | Biallelic Inactivation | Renal Cell
      KOL-Index: 10035

      Loss of heterozygosity (LOH) at the distal half of chromosome arm 11q is frequent in a variety of human tumors, including breast cancer, and is often associated with poor prognosis. In an ongoing attempt to locate and characterize the main target genes within this chromosome region, we first looked for aberrations in known genes either suggested to be involved in tumorigenesis or shown to suppress tumor formation. We examined 31 primary breast tumors showing LOH in 11q21-24 for mutations ...

      Known for Tslc1 Promoter | Proteins Breast | Dna Methylation | Genes Tumor | Cell Adhesion
      KOL-Index: 9629

      The circadian clock regulates daily variations in physiologic processes. CLOCK acts as a regulator in the circadian apparatus controlling the expression of other clock genes, including PER1. Clock genes have been implicated in cancer-related functions; in this work, we investigated CLOCK as a possible target of somatic mutations in microsatellite unstable colorectal cancers. Combining microarray gene expression data and public gene sequence information, we identified CLOCK as 1 of 790 ...

      Known for Colorectal Cancer | Circadian Gene | Clock Expression | Daily Variations | Somatic Mutations
      KOL-Index: 9531

      Inactivating germ-line mutations of LKB1 lead to Peutz-Jeghers syndrome (PJS). We have generated mice heterozygous for a targeted inactivating allele of Lkb1 and found that they develop severe gastrointestinal polyposis. In all cases, the polyps arising in the Lkb1+/- mice were found to be hamartomas that were histologically indistinguishable from polyps resected from PJS patients, indicating that Lkb1+/- mice model human PJS polyposis. No evidence for inactivation of the remaining ...

      Known for Jeghers Polyposis | Mouse Model | Lkb1 Mice | Pjs Patients | Signal Transduction
      KOL-Index: 9262

      Mutations in BRCA1 and BRCA2 account for a large portion of the inherited predisposition to breast and ovarian cancer. It was recently discovered that mutations in these two genes are less common in the Finnish population than expected. Because the genetic background of breast cancer, in particular, is largely obscure, it became necessary to search for mutations in other susceptibility genes. Because seven of our BRCA1 and BRCA2 mutation-negative families fulfilled the criteria of either ...

      Known for Fraumeni Syndrome | Tp53 Mutations | Brca1 Brca2 | Cancer Families | Germ Mutation

      Key People For Renal Cell Cancer

      Top KOLs in the world
      William Marston Linehan
      renal cell kidney cancer lindau disease
      WongHo M Chow
      cancer risk renal cell carcinoma united states
      Robert John Motzer
      germ cell advisory consultancy metastatic renal
      Joseph K McLAUGHLIN
      breast implants cancer risk united states
      Robert Alan Figlin
      renal cell carcinoma lung cancer kidney neoplasms
      Joseph F Jr Fraumeni
      united states lung cancer puerto rico

      STUK-Radiation and Nuclear Safety Authority, Helsinki, Finland. | STUK-Radiation and Nuclear Safety Authority, Helsinki, Finland | STUK – Radiation and Nuclear Safety Authority, Laippatie, Helsinki, Finland | Department of Medical Genetics, Genome-Sc

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.